Italy healthy-volunteer consent requirements

State why the volunteer is invited

Explain that the person is being invited because they meet the protocol's definition of a healthy volunteer, not because they need treatment. Describe screening and the possibility that findings may make the person ineligible. Explain what happens to screening data and samples if enrolment does not occur.

State that participation is voluntary and that not participating has no effect on normal health services or legal rights. The alternative is simply not to take part.

Be direct about benefit and uncertainty

Say that direct medical benefit is not expected. Do not imply that examinations, laboratory testing or medical supervision are treatment benefits. If clinically relevant screening findings may be detected, describe how they will be handled without promising a comprehensive health assessment.

For first-in-human, dose-escalation or early Phase I trials, explain the limited human experience, unknown risks, sentinel dosing, cohort progression, stopping rules and any possibility of severe or unpredictable harm. Put these facts in the key-information section.

Describe burden and restrictions

Give a practical schedule of screening, admission, confinement, dosing, meals, sleep, blood draws, urine collection, cardiac monitoring, imaging, follow-up and return visits. State total blood volume and the frequency of invasive procedures in understandable terms.

Explain restrictions on medicines, supplements, alcohol, nicotine, caffeine, exercise, diet, driving, work, blood donation and participation in other research. State how the research unit checks prior and concurrent trial participation and why washout periods matter.

Reproductive safeguards

Explain pregnancy testing, contraception, sperm or egg donation restrictions and the duration of precautions. Describe what happens if a participant or the partner of a participant becomes pregnant. Any follow-up of a pregnant partner requires an appropriate separate information and permission process. See the pregnancy follow-up guide.

Do not copy a generic contraception list if it differs from the protocol. Check the investigational product's reproductive risk and the approved schedule.

Reimbursement and financial arrangements

Describe every proposed reimbursement, allowance and documented loss-of-income arrangement accurately. Italian guidance prohibits incentives that could unduly influence consent. Reimbursement should reflect actual, documented trial-related expenses and the arrangement approved in Part II.

Do not present money as compensation for accepting risk. Explain calculation, payment timing, partial participation, early withdrawal, tax or documentation requirements and who pays. The financial terms must match the CCNCE reimbursement and allowance form and the site agreement.

Italian rules distinguish reimbursement from other compensatory arrangements and have changed over time. Submit the exact plan for ethics review rather than relying on a statement copied from an older form.

Samples, privacy and incidental findings

Explain mandatory pharmacokinetic, pharmacodynamic, safety and biomarker samples. Separate optional genetics, biobanking and future use. Use distinct choices and the secondary-use consent guide.

Provide the separate Italian privacy information and data-processing consent. Explain coding, record access, transfers, retention and withdrawal limits. Describe how clinically significant incidental findings from screening or trial procedures may be evaluated and communicated, including any limits on feedback.

Signatures and quality control

The volunteer and the doctor or investigator who conducted the consent discussion sign and date the approved form. Record place and time where required. Give the volunteer a copy. A capable volunteer who cannot write may use the approved alternative process with an impartial witness.

Use the full patient information and consent guide and run the patient-facing QC checklist. Return to the Italy CTIS guide hub for the wider dossier.